Why the study?
Does dexrazoxane prevent impaired mitochondrial function in childhood survivors of high-risk acute lymphoblastic leukemia treated with doxorubicin?
Does dexrazoxane prevent impaired mitochondrial function in childhood survivors of high-risk acute lymphoblastic leukemia treated with doxorubicin?
Concomitant use of dexrazoxane with doxorubicin in childhood ALL survivors is associated with a lower number of mtDNA copies per cell, suggesting it may abrogate doxorubicin-induced mitochondrial dysfunction.
Answers are grounded in this paper and cite their sources.
Dexrazoxane may mitigate doxorubicin-related mitochondrial changes in survivors; leaves open clinical cardiotoxicity benefit pending prospective trials.
BACKGROUND: Impaired cardiac function in doxorubicin-treated childhood cancer survivors is partly mediated by the disruption of mitochondrial energy production. Doxorubicin intercalates into mitochondrial DNA (mtDNA) and disrupts genes encoding for polypeptides that make adenosine triphosphate. METHODS: This cross-sectional study examined mtDNA copy numbers per cell and oxidative phosphorylation (OXPHOS) in peripheral blood mononuclear cells (PBMCs) in 64 childhood survivors of high-risk acute lymphoblastic leukemia (ALL) who had been treated on Dana-Farber Cancer Institute childhood ALL protocols and had received doxorubicin alone (42%) or doxorubicin with the cardioprotectant dexrazoxane (58%). The number of mtDNA copies per cell and the OXPHOS enzyme activity of nicotinamide adenine dinucleotide dehydrogenase (complex I [CI]) and cytochrome c oxidase (complex IV [CIV]) were measured with quantitative real-time polymerase chain reaction immunoassays and thin-layer chromatography, respectively. RESULTS: At a median follow-up of 7.8 years after treatment, the median number of mtDNA copies per cell for patients treated with doxorubicin alone (1106.3) was significantly higher than the median number for those who had also received dexrazoxane (310.5; P = .001). No significant differences were detected between the groups for CI or CIV activity. CONCLUSIONS: Doxorubicin-treated survivors had an increased number of PBMC mtDNA copies per cell, and concomitant use of dexrazoxane was associated with a lower number of mtDNA copies per cell. Because of a possible compensatory increase in mtDNA copies per cell to maintain mitochondrial function in the setting of mitochondrial dysfunction, overall OXPHOS activity was not different between the groups. The long-term sustainability of this compensatory response in these survivors at risk for cardiac dysfunction over their lifespan is concerning.
No takes yet. Share an insight, caveat, or question.
Lipshultz et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: